T cell play Eutilex raises W21B in series A

Immuno-oncology company Eutilex Co. Ltd. (Seoul, South Korea) raised W21 billion ($18.9 million) in a series A round from DS Asset Management, Kolon Investment, G.N. Tech Venture and SNU Bio Angel.

Eutilex said the money will support a Phase II study of lead candidate 4-1BB, an autologous T cell therapy targeting tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB; TNFRSF9; CD137). The company declined to disclose what indications will be evaluated in the trial...